Camrelizumab Plus Apatinib in Patients With Advanced Cervical Cancer (CLAP): A Multicenter, Open-Label, Single-Arm, Phase II Trial
Open accessAbstract
PURPOSE: Camrelizumab is an antibody against programmed death protein 1. We assessed the activity and safety of camrelizumab plus apatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor-2, in patients with advanced cervical cancer. METHODS: This multicenter, open-label, single-arm, phase II study enrolled patients with advanced cervical cancer who progressed after at least one line of systemic therapy. Patients received camrelizumab 200 mg every 2 weeks and apatinib 250 mg once per day. The primary end point was objective response rate (ORR) assessed by investigators per RECIST version 1.1. Key secondary end points were progression-free survival (PFS), overall survival (OS), duration of response, and safety. RESULTS: Forty-five patients were enrolled and received treatment. Median age was 51.0 years (range, 33-67 years), and 57.8% of patients had previously received two or more lines of chemotherapy for recurrent or metastatic disease. Ten patients (22.2%) had received bevacizumab. Median follow-up was 11.3 months (range, 1.0-15.5 months). ORR was 55.6% (95% CI, 40.0% to 70.4%), with two complete and 23 partial responses. Median PFS was 8.8 months (95% CI, 5.6 months to not estimable). Median duration of response and median OS were not reached. Treatment-related grade 3 or 4 adverse events (AEs) occurred in 71.1% of patients, and the most common AEs were hypertension (24.4%), anemia (20.0%), and fatigue (15.6%). The most common potential immune-related AEs included grade 1-2 hypothyroidism (22.2%) and reactive cutaneous capillary endothelial proliferation (8.9%). CONCLUSION: Camrelizumab plus apatinib had promising antitumor activity and manageable toxicities in patients with advanced cervical cancer. Larger randomized controlled trials are warranted to validate our findings.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Combination therapies such as sintilimab plus anlotinib, sintilimab plus IBI305, camrelizumab plus apatinib, and toripalimab plus axitinib demonstrated potent antitumor effects in multiple types of cancers.
“Combination therapies such as sintilimab plus anlotinib, sintilimab plus IBI305 (bevacizumab biosimilar), camrelizumab plus apatinib, and toripalimab plus axitinib demonstrated potent antitumor effects in multiple types of cancers [22, 114–120].”
From Combination strategies with PD-1/PD-L1 blockade: current advances and future directions (2022) · cites this paper as [116]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109 · see citing works
Cancer statistics in China, 2015
Chen, W., Zheng, R., Baade, P. D., Zhang, S., Zeng, H., Bray, F., Jemal, A., Yu, X. Q., & He, J. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21338 · Cited by 17,038 · see citing works
Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
Fukumura, D., Kloepper, J., Amoozgar, Z., Duda, D. G., & Jain, R. K. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.29 · Cited by 2,027 · see citing works
Rini, B. I., Escudier, B. J., Tomczak, P., Каприн, А. Д., Szczylik, C. A., Hutson, T. E., Michaelson, M. D., Горбунова, В. А., Gore, M. E., Русаков, И. Г., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)61613-9 · Cited by 1,843 · see citing works
Improved Survival with Bevacizumab in Advanced Cervical Cancer
Tewari, K. S., Sill, M. W., Long, H. J., Penson, R. T., Huang, H. Q., Ramondetta, L. M., Landrum, L. M., Oaknin, A., Reid, T. J. A., Leitão, M. M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1309748 · Cited by 1,510 · see citing works
Chung, H. C., Ros, W., Delord, J., Perets, R., Italiano, A., Shapira‐Frommer, R., Manzuk, L., Piha-Paul, S. A., Xu, L., Zeigenfuss, S., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.01265 · Cited by 1,075 · see citing works
Stevanović, S., Draper, L. M., Langhan, M. M., Campbell, T. E., Kwong, M. L. M., Wunderlich, J. R., Dudley, M. E., Yang, J. C., Sherry, R. M., Kammula, U. S., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.9093 · Cited by 682 · see citing works
Moore, D. H., Blessing, J. A., McQuellon, R. P., Thaler, H. T., Cella, D. F., Bénda, J., Miller, D. S., Olt, G. J., King, S. A., Boggess, J. F., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.04.170 · Cited by 632 · see citing works
Frenel, J., Tourneau, C. L., O’Neil, B. H., Ott, P. A., Piha-Paul, S. A., Gomez‐Roca, C., van Brummelen, E. M. J., Rugo, H. S., Thomas, S., Saraf, S., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.74.5471 · Cited by 537 · see citing works
Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer
Makker, V., Taylor, M. H., Aghajanian, C., Oaknin, A., Mier, J., Cohn, A. L., Romeo, M., Bratos, R., Brose, M. S., DiSimone, C., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02627 · Cited by 522 · see citing works
Xu, J., Zhang, Y., Jia, R., Yue, C., Chang, L., Liu, R., Zhang, G., Zhao, C., Zhang, Y., Chen, C., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2484 · Cited by 498 · see citing works
Self-citationFang, W., Yang, Y., Ma, Y., Hong, S., Lin, L., He, X., Xiong, J., Li, P., Zhao, H., Huang, Y., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30495-9 · Cited by 489 · see citing works
Naumann, R. W., Hollebecque, A., Meyer, T., Devlin, M.-J., Oaknin, A., Kerger, J. N., López-Picazo, J. M., Machiels, J.-P., Delord, J., Evans, T. R. J., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00739 · Cited by 440 · see citing works
Atkins, M. B., Plimack, E. R., Puzanov, I. J., Fishman, M., McDermott, D. F., Cho, D. C., Vaishampayan, U. N., George, S., Olencki, T. E., Tarazi, J., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30081-0 · Cited by 370 · see citing works
Monk, B. J., Sill, M. W., Burger, R. A., Gray, H. J., Buekers, T., & Roman, L. D. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.9043 · Cited by 346 · see citing works
Van der Veldt, A. A. M., Lubberink, M., Bahce, I., Walraven, M., de Boer, M. P., Greuter, H. N. J. M., Hendrikse, N. H., Eriksson, J., Windhorst, A. D., Postmus, P. E., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2011.11.023 · Cited by 337 · see citing works
Enhanced expression of PD L1 in cervical intraepithelial neoplasia and cervical cancers
Mezache, L., Paniccia, B., Nyinawabera, A., & Nuovo, G. J. (2015) · Modern Pathology · doi:10.1038/modpathol.2015.108 · Cited by 311 · see citing works
Heeren, A. M., Punt, S., Bleeker, M. C. G., Gaarenstroom, K. N., van der Velden, J., Kenter, G. G., de Gruijl, T. D., & Jordanova, E. S. (2016) · Modern Pathology · doi:10.1038/modpathol.2016.64 · Cited by 309 · see citing works
Enwere, E. K., Kornaga, E. N., Dean, M. L., Koulis, T. A., Phan, T., Kalantarian, M., Köbel, M., Ghatage, P., Magliocco, A. M., Lees‐Miller, S. P., et al. (2017) · Modern Pathology · doi:10.1038/modpathol.2016.221 · Cited by 188 · see citing works
Liu, J., Liu, Q., Li, Y., Li, Q., Su, F., Yao, H., Su, S., Wang, Q., Jin, L., Wang, Y., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000696 · Cited by 183 · see citing works
Self-citationBookman, M. A., Blessing, J. A., Hanjani, P., Herzog, T. J., & Andersen, W. A. (2000) · Gynecologic Oncology · doi:10.1006/gyno.2000.5807 · Cited by 125 · see citing works
Qin, Y. W., Ekmekçioglu, S., Forget, M., Székvölgyi, L., Hwu, P., Grimm, E. A., Jazaeri, A. A., & Roszik, J. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00689 · Cited by 74 · see citing works
Alberts, D. S., Blessing, J. A., Landrum, L. M., Warshal, D. P., Martin, L. P., Rose, S. L., Bonebrake, A. J., & Ramondetta, L. M. (2012) · Gynecologic Oncology · doi:10.1016/j.ygyno.2012.09.008 · Cited by 67 · see citing works
Phase II Clinical Trial of Docetaxel in Refractory Squamous Cell Carcinoma of the Cervix
García, A. A., Blessing, J. A., Vaccarello, L., & Roman, L. D. (2007) · American Journal of Clinical Oncology · doi:10.1097/coc.0b013e31803377c8 · Cited by 65 · see citing works
PD-L1 expression in squamous-cell carcinoma and adenocarcinoma of the lung
Janžič, U., Kern, I., Janžič, A., Čavka, L., & Čufer, T. (2017) · Radiology and Oncology · doi:10.1515/raon-2017-0037 · Cited by 54 · see citing works
Chowdhury, S., Infante, J. R., Hawkins, R. D., et al. (2021) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2021.04.007 · Cited by 38 · see citing works
Xiao, Y. P., Cheng, H., Wang, L., et al. (2019) · Journal of Gynecologic Oncology · doi:10.3802/jgo.2020.31.e2 · Cited by 18 · see citing works
Yu, J., Xu, Z., Li, A., et al. (2019) · Drug Design Development and Therapy · doi:10.2147/dddt.s214743 · Cited by 14 · see citing works
Friedman, C. F., Snyder, A., Sharon, E., et al. (2019) · Gynecologic Oncology · doi:10.1016/j.ygyno.2019.04.045 · Cited by 10 · see citing works
Su, M., Gao, Y., Ye, X., et al. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s230406 · Cited by 8 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Combination strategies with PD-1/PD-L1 blockade: current advances and future directions
Yi, M., Zheng, X., Niu, M., Zhu, S., Ge, H., & Wu, K. (2022) · Molecular Cancer · doi:10.1186/s12943-021-01489-2 · Cited by 1,445 · see citing works
- Authors
- Lan, C., Shen, J., Wang, Y., Li, J., Liu, Z., He, M., Cao, X., Ling, J., Huang, J., Zheng, M., Zou, G., Yan, H., Liu, Q., Yang, F., Wei, W., Deng, Y., Xiong, Y., & Huang, X.
- Affiliations
- Sun Yat-sen University (CN)
- Panyu District Central Hospital (CN)
- Corresponding author
- Huang, Xin
- ORCID
- Venue
- Journal of Clinical Oncology
- Published
- 2020-12-01
- Volume
- 38
- Issue
- 34
- Pages
- 4095-4106
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- PMC
- PMC7768345
- OpenAlex
- W3032571309
- Cited by
- 210
- References
- 30
- Citations by year
- 2026: 20 · 2025: 34 · 2024: 41 · 2023: 41 · 2022: 50 · 2021: 24
- FWCI
- 17.59
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- Locations
- Journal of Clinical Oncology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Jiangsu Hengrui Medicine
- Topics
- Health Sciences › Medicine › Obstetrics and Gynecology › Endometrial and Cervical Cancer Treatments
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Epidemiology › Cervical Cancer and HPV Research
- Keywords
- camrelizumab, apatinib, advanced cervical cancer, PD-1 inhibitors, VEGFR-2 inhibitors, combination immunotherapy, objective response rate, progression-free survival, immune-related adverse events
- MeSH terms
- Progression-Free Survival, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Uterine Cervical Neoplasms, Female, Humans, Middle Aged, Pyridines, Survival Rate, Protein Kinase Inhibitors, Kaplan-Meier Estimate, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
